🔗 Visit the ClinicalTrials.gov page for NCT02797704
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Corneal neovascularization. | Curr Opin Ophthalmol | 2001 | 3.22 |
| 2 | Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). | Trans Am Ophthalmol Soc | 2006 | 2.12 |
| 3 | Corneal neovascularization: an anti-VEGF therapy review. | Surv Ophthalmol | 2012 | 1.21 |
| 4 | Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). | Ocul Surf | 2012 | 1.08 |
| 5 | Corneal penetration of topical and subconjunctival bevacizumab. | Invest Ophthalmol Vis Sci | 2011 | 1.07 |
| 6 | Aflibercept in wet AMD: specific role and optimal use. | Drug Des Devel Ther | 2013 | 0.97 |
| 7 | Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. | Mol Vis | 2011 | 0.88 |
| 8 | VEGF Trap(R1R2) suppresses experimental corneal angiogenesis. | Eur J Ophthalmol | 2010 | 0.81 |